Drugs / JNJ-95597528
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07230860 | Jan → Nov 2026 expected | atopic eczema | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-95597528 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07230860 ↗ |
| Route | Subcutaneous | “JNJ-95597528 will be administered subcutaneously.” NCT07230860 ↗ |